HR 5850
118th Congress
House
Health
Abortion
Drug safety, medical device, and laboratory regulation
Prescription drugs
To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone, and for other purposes.
Everywhere this bill has been
3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Oct 6, 2023
Referred to the Subcommittee on Health.
Sep 29, 2023
Referred to the House Committee on Energy and Commerce.
Sep 29, 2023
Introduced in House
What's happening now
Referred to the Subcommittee on Health.
Committees of jurisdiction
2
Cosponsors
1